BioAegis Therapeutics https://www.bioaegistherapeutics.com/ The Power of Innate Immunity Mon, 15 Dec 2025 16:30:45 +0000 en hourly 1 https://wordpress.org/?v=6.9 https://www.bioaegistherapeutics.com/wp-content/uploads/2020/02/cropped-BioAegis-Favicon500-32x32.webp BioAegis Therapeutics https://www.bioaegistherapeutics.com/ 32 32 Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized with Critical COVID-19 Pneumonia https://pubmed.ncbi.nlm.nih.gov/34396087/#new_tab?utm_source=rss&utm_medium=rss&utm_campaign=recombinant-human-plasma-gelsolin-rhu-pgsn-in-a-patient-hospitalized-with-critical-covid-19-pneumonia https://pubmed.ncbi.nlm.nih.gov/34396087/#new_tab#respond Mon, 15 Dec 2025 16:28:36 +0000 https://www.bioaegistherapeutics.com/?p=5888 Catteeuw JV, DiNubile MJ. Clin Infect Pract. 2021 Nov;12:100088. doi: 10.1016/j.clinpr.2021.100088. Epub 2021 Aug 10. PMID: 34396087; PMCID: PMC8353968.

The post Recombinant Human Plasma Gelsolin (rhu-pGSN) in a Patient Hospitalized with Critical COVID-19 Pneumonia appeared first on BioAegis Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/34396087/#new_tab/feed/ 0 Key Component of Innate Immunity https://www.bioaegistherapeutics.com/feature/key-component-of-innate-immunity/?utm_source=rss&utm_medium=rss&utm_campaign=key-component-of-innate-immunity Thu, 16 Oct 2025 17:01:29 +0000 https://www.bioaegistherapeutics.com/?p=4853 Plasma Gelsolin is a key component of the innate immune system – the first line of defense against threats to the body. This innate system is not pathogen-specific and reacts equally well to a wide variety of organisms.

The post Key Component of Innate Immunity appeared first on BioAegis Therapeutics.

]]> Regulates Inflammation https://www.bioaegistherapeutics.com/feature/regulates-inflammation/?utm_source=rss&utm_medium=rss&utm_campaign=regulates-inflammation Thu, 16 Oct 2025 16:51:47 +0000 https://www.bioaegistherapeutics.com/?p=4843 Plasma gelsolin’s unique role is to modulate the necessary inflammatory response so that what was intended to be a mechanism of healing does not become an instrument of morbidity and death.

The post Regulates Inflammation appeared first on BioAegis Therapeutics.

]]> August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) https://www.bioaegistherapeutics.com/news/august-20-2025-bioaegis-therapeutics-awarded-second-fda-fast-track-designation-for-recombinant-human-gelsolin-to-treat-inflammasome-driven-decompression-sickness-dcs/?utm_source=rss&utm_medium=rss&utm_campaign=august-20-2025-bioaegis-therapeutics-awarded-second-fda-fast-track-designation-for-recombinant-human-gelsolin-to-treat-inflammasome-driven-decompression-sickness-dcs Wed, 20 Aug 2025 15:35:12 +0000 https://www.bioaegistherapeutics.com/?p=4707 Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in recent months highlights broad potential of rhu-pGSN across multiple diverse inflammation-driven conditions. NORTH BRUNSWICK, N.J., August 20, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of […]

The post August 20, 2025: BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS) appeared first on BioAegis Therapeutics.

]]> June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/june-17-2025-bioaegis-therapeutics-receives-fda-fast-track-designation-for-lead-product-recombinant-human-gelsolin-for-the-treatment-of-acute-respiratory-distress-syndrome-ards/?utm_source=rss&utm_medium=rss&utm_campaign=june-17-2025-bioaegis-therapeutics-receives-fda-fast-track-designation-for-lead-product-recombinant-human-gelsolin-for-the-treatment-of-acute-respiratory-distress-syndrome-ards Tue, 17 Jun 2025 14:24:30 +0000 https://www.bioaegistherapeutics.com/?p=4665 Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.  Global Phase 2b clinical trial underway evaluating rhu-pGSN for the treatment of moderate to severe ARDS.  NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech […]

The post June 17, 2025: BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> June 10, 2025: BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS) https://www.bioaegistherapeutics.com/news/june-10-2025-bioaegis-therapeutics-announces-us-navy-contract-to-support-phase-2-study-of-recombinant-human-gelsolin-for-inflammasome-driven-decompression-sickness-dcs/?utm_source=rss&utm_medium=rss&utm_campaign=june-10-2025-bioaegis-therapeutics-announces-us-navy-contract-to-support-phase-2-study-of-recombinant-human-gelsolin-for-inflammasome-driven-decompression-sickness-dcs Tue, 10 Jun 2025 18:25:06 +0000 https://www.bioaegistherapeutics.com/?p=4653 Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of  inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers. NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory […]

The post June 10, 2025: BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS) appeared first on BioAegis Therapeutics.

]]> May 6, 2025: BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) https://www.bioaegistherapeutics.com/news/may-6-2025-bioaegis-therapeutics-announces-site-activation-and-patient-recruitment-underway-in-13-countries-in-phase-2b-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-re/?utm_source=rss&utm_medium=rss&utm_campaign=may-6-2025-bioaegis-therapeutics-announces-site-activation-and-patient-recruitment-underway-in-13-countries-in-phase-2b-clinical-trial-of-gelsolin-an-immune-regulator-for-the-treatment-of-acute-re Tue, 06 May 2025 01:55:20 +0000 https://www.bioaegistherapeutics.com/?p=4621 600-patient study to assess efficacy of rhu-pGSN,  an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens.  Results from this landmark study expected to inform therapeutic strategies beyond ARDS, positioning rhu-pGSN as a promising intervention across a spectrum of acute and chronic inflammatory diseases.  NORTH BRUNSWICK, N.J., May 6, 2025 […]

The post May 6, 2025: BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS) appeared first on BioAegis Therapeutics.

]]> March 18, 2025: BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences https://www.bioaegistherapeutics.com/news/march-18-2025-bioaegis-therapeutics-to-highlight-lead-product-gelsolins-critical-role-in-immune-function-at-upcoming-conferences/?utm_source=rss&utm_medium=rss&utm_campaign=march-18-2025-bioaegis-therapeutics-to-highlight-lead-product-gelsolins-critical-role-in-immune-function-at-upcoming-conferences Tue, 18 Mar 2025 18:36:40 +0000 https://www.bioaegistherapeutics.com/?p=4531 Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.  COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025.  NORTH BRUNSWICK, N.J., March 18, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, […]

The post March 18, 2025: BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences appeared first on BioAegis Therapeutics.

]]> March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference https://www.bioaegistherapeutics.com/event/march-27-28-2025-medinvest-biotech-pharma-investor-conference/?utm_source=rss&utm_medium=rss&utm_campaign=march-27-28-2025-medinvest-biotech-pharma-investor-conference Fri, 07 Mar 2025 18:36:39 +0000 https://www.bioaegistherapeutics.com/?p=4485 BioAegis COO and Co-founder, Valerie Ceva, was invited to present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City. The presentation, “Conquering Disease Driven by Excess Inflammation” will highlight BioAegis’ novel, host-directed immune regulator protein. The presentation will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (ARDS), and its phase […]

The post March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference appeared first on BioAegis Therapeutics.

]]> March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) https://www.bioaegistherapeutics.com/event/march-18-21-2025-44th-annual-international-symposium-on-intensive-care-and-emergency-medicine-isicem/?utm_source=rss&utm_medium=rss&utm_campaign=march-18-21-2025-44th-annual-international-symposium-on-intensive-care-and-emergency-medicine-isicem Fri, 07 Mar 2025 06:58:00 +0000 https://www.bioaegistherapeutics.com/?p=4493 BioAegis is a sponsor of the upcoming International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium from March 18-21, 2025. Current information on our ongoing ARDS trial will be presented at this key critical care conference.

The post March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) appeared first on BioAegis Therapeutics.

]]>